Cargando…

Clinical Indicators of Symptom Dimensions and Cognitive Ability in Schizophrenia

INTRODUCTION: Schizophrenia is a heterogeneous disorder and it is unknown what causes individual variability in symptoms and cognitive ability. OBJECTIVES: To examine the association between nine clinical predictors measurable at the onset of schizophrenia and five phenotype dimensions: positive, ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Farakish, L., Legge, S., Owen, M., O’Donovan, M., Walters, J., Cardno, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563343/
http://dx.doi.org/10.1192/j.eurpsy.2022.317
_version_ 1784808381284876288
author Farakish, L.
Legge, S.
Owen, M.
O’Donovan, M.
Walters, J.
Cardno, A.
author_facet Farakish, L.
Legge, S.
Owen, M.
O’Donovan, M.
Walters, J.
Cardno, A.
author_sort Farakish, L.
collection PubMed
description INTRODUCTION: Schizophrenia is a heterogeneous disorder and it is unknown what causes individual variability in symptoms and cognitive ability. OBJECTIVES: To examine the association between nine clinical predictors measurable at the onset of schizophrenia and five phenotype dimensions: positive, negative (diminished expressivity), negative (motivation and pleasure), disorganised symptoms and cognitive ability. METHODS: 852 participants (mean age 49 years old) with a diagnosis of schizophrenia or schizoaffective depression were included from the CardiffCOGS cross-sectional sample. Phenotype dimensions were created using confirmatory factor analysis and a 5-factor model. Associations were tested using linear regression, adjusting for age and sex. A Bonferroni correction was applied for (p<1.1x10(-3)) for multiple testing. RESULTS: Age of onset of psychosis was significantly associated with positive symptoms (β=-0.18, p=4.0 x10(-6)). Lower premorbid IQ was associated with diminished expressivity (β=-0.25, p= 7.0x10(-13)), reduced motivation and pleasure (β=-0.23, p= 4.3x10(-11)), disorganised symptoms (β=-0.14, p= 7.6x10(-5)) and reduced cognition (β=0.54, p= 4.8x10(-77)). Poor premorbid social adjustment held associations with all except positive. Developmental delay was associated with reduced cognition (β=-0.35, p= 4.3x10(-5)). Cannabis use (year before onset), psychosocial stressors (within 6 months), childhood abuse and family history of schizophrenia held no associations. CONCLUSIONS: Clinical indicators measurable at schizophrenia onset are associated with lifetime symptom variability. A younger psychosis onset is associated with more severe positive symptoms, suggesting possible age-targeted management. Pre-established links of lower premorbid IQ with poor premorbid social adjustment and negative symptom severity with cognition are strengthened. Further investigation could potentially improve diagnosis and guide treatment choice for aspects of schizophrenia with poor outcomes. DISCLOSURE: No significant relationships.
format Online
Article
Text
id pubmed-9563343
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-95633432022-10-17 Clinical Indicators of Symptom Dimensions and Cognitive Ability in Schizophrenia Farakish, L. Legge, S. Owen, M. O’Donovan, M. Walters, J. Cardno, A. Eur Psychiatry Abstract INTRODUCTION: Schizophrenia is a heterogeneous disorder and it is unknown what causes individual variability in symptoms and cognitive ability. OBJECTIVES: To examine the association between nine clinical predictors measurable at the onset of schizophrenia and five phenotype dimensions: positive, negative (diminished expressivity), negative (motivation and pleasure), disorganised symptoms and cognitive ability. METHODS: 852 participants (mean age 49 years old) with a diagnosis of schizophrenia or schizoaffective depression were included from the CardiffCOGS cross-sectional sample. Phenotype dimensions were created using confirmatory factor analysis and a 5-factor model. Associations were tested using linear regression, adjusting for age and sex. A Bonferroni correction was applied for (p<1.1x10(-3)) for multiple testing. RESULTS: Age of onset of psychosis was significantly associated with positive symptoms (β=-0.18, p=4.0 x10(-6)). Lower premorbid IQ was associated with diminished expressivity (β=-0.25, p= 7.0x10(-13)), reduced motivation and pleasure (β=-0.23, p= 4.3x10(-11)), disorganised symptoms (β=-0.14, p= 7.6x10(-5)) and reduced cognition (β=0.54, p= 4.8x10(-77)). Poor premorbid social adjustment held associations with all except positive. Developmental delay was associated with reduced cognition (β=-0.35, p= 4.3x10(-5)). Cannabis use (year before onset), psychosocial stressors (within 6 months), childhood abuse and family history of schizophrenia held no associations. CONCLUSIONS: Clinical indicators measurable at schizophrenia onset are associated with lifetime symptom variability. A younger psychosis onset is associated with more severe positive symptoms, suggesting possible age-targeted management. Pre-established links of lower premorbid IQ with poor premorbid social adjustment and negative symptom severity with cognition are strengthened. Further investigation could potentially improve diagnosis and guide treatment choice for aspects of schizophrenia with poor outcomes. DISCLOSURE: No significant relationships. Cambridge University Press 2022-09-01 /pmc/articles/PMC9563343/ http://dx.doi.org/10.1192/j.eurpsy.2022.317 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Farakish, L.
Legge, S.
Owen, M.
O’Donovan, M.
Walters, J.
Cardno, A.
Clinical Indicators of Symptom Dimensions and Cognitive Ability in Schizophrenia
title Clinical Indicators of Symptom Dimensions and Cognitive Ability in Schizophrenia
title_full Clinical Indicators of Symptom Dimensions and Cognitive Ability in Schizophrenia
title_fullStr Clinical Indicators of Symptom Dimensions and Cognitive Ability in Schizophrenia
title_full_unstemmed Clinical Indicators of Symptom Dimensions and Cognitive Ability in Schizophrenia
title_short Clinical Indicators of Symptom Dimensions and Cognitive Ability in Schizophrenia
title_sort clinical indicators of symptom dimensions and cognitive ability in schizophrenia
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563343/
http://dx.doi.org/10.1192/j.eurpsy.2022.317
work_keys_str_mv AT farakishl clinicalindicatorsofsymptomdimensionsandcognitiveabilityinschizophrenia
AT legges clinicalindicatorsofsymptomdimensionsandcognitiveabilityinschizophrenia
AT owenm clinicalindicatorsofsymptomdimensionsandcognitiveabilityinschizophrenia
AT odonovanm clinicalindicatorsofsymptomdimensionsandcognitiveabilityinschizophrenia
AT waltersj clinicalindicatorsofsymptomdimensionsandcognitiveabilityinschizophrenia
AT cardnoa clinicalindicatorsofsymptomdimensionsandcognitiveabilityinschizophrenia